{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:01:04Z","timestamp":1755219664889,"version":"3.43.0"},"posted":{"date-parts":[[2025,5,6]]},"group-title":"In Review","reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,1,16]]},"abstract":"<title>Abstract<\/title>\n        <p><bold>Background <\/bold>Predictors of major adverse kidney events (MAKE) in focal segmental glomerulosclerosis (FSGS) have not been previously explored within large, real-world populations. The study aim was to evaluate population-level predictors of MAKE for patients with FSGS from health system data.\n<bold>Methods<\/bold> The study population was derived from electronic health records from Providence and University of California Los Angeles Health. Cox proportional hazards models were used to estimate the effects of clinical and non-clinical variables including age, gender, race and ethnicity, health system, health insurance, healthcare utilization, estimated glomerular filtration rate (eGFR), diabetes, hypertension, and prescription medications as predictors of MAKE defined as: \u226540% eGFR decline, kidney failure (eGFR &lt;15 mL\/min\/1.73 m<sup>2<\/sup>, administrative codes for kidney failure, dialysis, or transplant) and death.\n<bold>Results<\/bold> Adults with FSGS (N=629) were 54% (n=342) men and 53\u00b117 (mean\u00b1SD) years old. Baseline eGFR was 60\u00b130 mL\/min\/1.73 m<sup>2<\/sup>, while median (interquartile range) urine albumin\/creatinine ratio (UACR) and urine protein\/creatinine ratio (UPCR) were 1,430 (520-2,630) mg\/g and 1.6 (0.5-3.9) g\/g, respectively. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers were prescribed to 76% (n=475), while corticosteroids and other immunomodulators were prescribed in 47% (n=297) and 12% (n=74), respectively. MAKE were observed in 42% (n=262) of study participants over a median of 2.9 (1.4-4.5) years. Higher hazard for MAKE was associated with above-median UACR or UPCR (HR [95% CI] (3.46 [2.28-5.23]) in patients with available measures, prescription for non-corticosteroid immunomodulator (1.87 [1.32-2.65]), non-commercial health insurance (1.78 [1.36-2.33]), hospitalization (1.64 [1.25-2.15]), lower eGFR per 10 mL\/min\/1.73 m<sup>2<\/sup> 1.25 [1.18-1.32]), number of outpatient visits (1.03 [1.01-1.05]) and lower hazard for MAKE was associated with older age (0.89 [0.82-0.98]).\n<bold>Conclusions<\/bold> Substantial loss of kidney function or kidney failure occurred in more than four in ten patients with FSGS by a median of three years. MAKE were predicted by unique population level factors, such as healthcare utilization and insurance type, which may help to identify patients with FSGS, who could most benefit from diagnostic testing and interventions to improve clinical outcomes.<\/p>","DOI":"10.21203\/rs.3.rs-5844460\/v1","type":"posted-content","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T05:38:56Z","timestamp":1746509936000},"source":"Crossref","is-referenced-by-count":0,"title":["Population Risk Predictors of Major Adverse Kidney Events in Patients with Focal Segmental Glomerulosclerosis from the CURE-CKD Registry"],"prefix":"10.21203","author":[{"given":"Susanne B.","family":"Nicholas","sequence":"first","affiliation":[{"name":"University of California, Los Angeles"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey M.","family":"Kornowske","sequence":"additional","affiliation":[{"name":"Providence Inland Northwest Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cami R.","family":"Jones","sequence":"additional","affiliation":[{"name":"Providence Inland Northwest Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenn B.","family":"Daratha","sequence":"additional","affiliation":[{"name":"Providence Inland Northwest Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radica Z.","family":"Alicic","sequence":"additional","affiliation":[{"name":"Providence Inland Northwest Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina L.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Providence Inland Northwest Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[{"name":"Washington State University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Bensink","sequence":"additional","affiliation":[{"name":"Travere Therapeutics Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Gong","sequence":"additional","affiliation":[{"name":"Travere Therapeutics Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith C.","family":"Norris","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Providence Inland Northwest Health"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal Segmental Glomerulosclerosis","volume":"12","author":"Rosenberg AZ","year":"2017","unstructured":"Rosenberg AZ, Kopp JB. Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol. 2017;12(3):502\u201317.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ajmg.c.31990","article-title":"Monogenic focal segmental glomerulosclerosis: A conceptual framework for identification and management of a heterogeneous disease","volume":"190","author":"Sambharia M","year":"2022","unstructured":"Sambharia M, Rastogi P, Thomas CP. Monogenic focal segmental glomerulosclerosis: A conceptual framework for identification and management of a heterogeneous disease. Am J Med Genet C Semin Med Genet. 2022;190(3):377\u201398.","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"KDIGO. 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021, 100(4s):S1-s276.","DOI":"10.1016\/j.kint.2021.05.021"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/0272-6386(95)90120-5","article-title":"Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment","volume":"25","author":"Rydel JJ","year":"1995","unstructured":"Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis. 1995;25(4):534\u201342.","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.mayocp.2017.09.011","article-title":"The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study","volume":"92","author":"Hommos MS","year":"2017","unstructured":"Hommos MS, De Vriese AS, Alexander MP, Sethi S, Vaughan L, Zand L, Bharucha K, Lepori N, Rule AD, Fervenza FC. The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study. Mayo Clin Proc. 2017;92(12):1772\u201381.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/ndt\/gfx189","article-title":"Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey","volume":"33","author":"O'Shaughnessy MM","year":"2018","unstructured":"O'Shaughnessy MM, Hogan SL, Thompson BD, Coppo R, Fogo AB, Jennette JC. Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey. Nephrol Dial Transpl. 2018;33(4):661\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin BH","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):753\u201379.","journal-title":"Kidney Int"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1097\/01.ASN.0000135051.62500.97","article-title":"Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants","volume":"15","author":"Chun MJ","year":"2004","unstructured":"Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol. 2004;15(8):2169\u201377.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0272-6386(96)90098-0","article-title":"The racial prevalence of glomerular lesions in nephrotic adults","volume":"27","author":"Korbet SM","year":"1996","unstructured":"Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis. 1996;27(5):647\u201351.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.2215\/CJN.13091215","article-title":"Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS","volume":"11","author":"Laurin LP","year":"2016","unstructured":"Laurin LP, Gasim AM, Derebail VK, McGregor JG, Kidd JM, Hogan SL, Poulton CJ, Detwiler RK, Jennette JC, Falk RJ, et al. Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS. Clin J Am Soc Nephrol. 2016;11(10):1752\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"sfae131","DOI":"10.1093\/ckj\/sfae131","article-title":"Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort","volume":"17","author":"Stamellou E","year":"2024","unstructured":"Stamellou E, Nadal J, Hendry B, Mercer A, Bechtel-Walz W, Schiffer M, Eckardt KU, Kramann R, Moeller MJ, Floege J. Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort. Clin Kidney J. 2024;17(7):sfae131.","journal-title":"Clin Kidney J"},{"issue":"3","key":"ref12","first-page":"115","article-title":"Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes","volume":"33","author":"Wehrmann M","year":"1990","unstructured":"Wehrmann M, Bohle A, Held H, Schumm G, Kendziorra H, Pressler H. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol. 1990;33(3):115\u201322.","journal-title":"Clin Nephrol"},{"year":"2021","author":"Forster BM","key":"ref13","unstructured":"Forster BM, Nee R, Little DJ, Greasley PJ, Hughes JB, Gordon SM, Olson SW. Focal Segmental Glomerulosclerosis, Risk Factors for End Stage Kidney Disease, and Response to Immunosuppression. Kidney360 2021, 2(1):105\u2013113."},{"issue":"12","key":"ref14","doi-asserted-by":"crossref","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry","volume":"2","author":"Tuttle KR","year":"2019","unstructured":"Tuttle KR, Alicic RZ, Duru OK, Jones CR, Daratha KB, Nicholas SB, McPherson SM, Neumiller JJ, Bell DS, Mangione CM, et al. Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry. JAMA Netw Open. 2019;2(12):e1918169.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/s12882-019-1558-9","article-title":"Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD","volume":"20","author":"Norris KC","year":"2019","unstructured":"Norris KC, Duru OK, Alicic RZ, Daratha KB, Nicholas SB, McPherson SM, Bell DS, Shen JI, Jones CR, Moin T, et al. Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD. BMC Nephrol. 2019;20(1):416.","journal-title":"BMC Nephrol"},{"issue":"19","key":"ref16","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race","volume":"385","author":"Inker LA","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737\u201349.","journal-title":"N Engl J Med"},{"key":"ref17","unstructured":"SSA's Death Information. https:\/\/www.ssa.gov\/dataexchange\/request_dmf.html"},{"author":"Statewide D","key":"ref18","unstructured":"Statewide D, Profiles. https:\/\/data.chhs.ca.gov\/dataset\/statewide-death-profiles"},{"key":"ref19","unstructured":"R Core Team. A language and environment for statistical computing. https:\/\/www.R-project.org\/ Accessed 6\/21\/2022. In. R Foundation for Statistical Computing."},{"year":"2023","author":"Therneau TAE","key":"ref20","unstructured":"Therneau TAE, Crowson C. A Package for Survival Analysis in R_. R package version 3.3-1. https:\/\/github.com\/therneau\/survival. Acessed 6\/21\/2023. In.; 2023."},{"key":"ref21","unstructured":"TA G. _prodlim: Product-Limit Estimation for Censored Event History Analysis_. R package version 2023.03.31. https:\/\/CRAN.R-project.org\/package=prodlim. In.; 2013."},{"key":"ref22","unstructured":"What\u2019s the difference. between Medicare and Medicaid? Accessed 10\/2\/2024. https:\/\/www.hhs.gov\/answers\/medicare-and-medicaid\/what-is-the-difference-between-medicare-medicaid\/index.html"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"100748","DOI":"10.1016\/j.xkme.2023.100748","article-title":"Clinical Characteristics and Histopathology in Adults With Focal Segmental Glomerulosclerosis","volume":"6","author":"Tuttle KR","year":"2024","unstructured":"Tuttle KR, Abner CW, Walker PD, Wang K, Rava A, Heo J, Bunke M. Clinical Characteristics and Histopathology in Adults With Focal Segmental Glomerulosclerosis. Kidney Med. 2024;6(2):100748.","journal-title":"Kidney Med"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"e0315302","DOI":"10.1371\/journal.pone.0315302","article-title":"Epidemiology and burden of focal segmental glomerulosclerosis among United States Veterans: An analysis of Veteran's Affairs data","volume":"19","author":"Goldschmidt D","year":"2024","unstructured":"Goldschmidt D, Bensink ME, Zhou ZY, Shi S, Lin Y, Shi L. Epidemiology and burden of focal segmental glomerulosclerosis among United States Veterans: An analysis of Veteran's Affairs data. PLoS ONE. 2024;19(12):e0315302.","journal-title":"PLoS ONE"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"e012674","DOI":"10.1136\/bmjopen-2016-012674","article-title":"What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis","volume":"7","author":"Whiting P","year":"2017","unstructured":"Whiting P, Morden A, Tomlinson LA, Caskey F, Blakeman T, Tomson C, Stone T, Richards A, Savovi\u0107 J, Horwood J. What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis. BMJ Open. 2017;7(4):e012674.","journal-title":"BMJ Open"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"e012690","DOI":"10.1136\/bmjopen-2016-012690","article-title":"Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study","volume":"6","author":"Mansfield KE","year":"2016","unstructured":"Mansfield KE, Nitsch D, Smeeth L, Bhaskaran K, Tomlinson LA. Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study. BMJ Open. 2016;6(12):e012690.","journal-title":"BMJ Open"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2215\/CJN.14021118","article-title":"Stopping RAS Inhibitors to Minimize AKI: More Harm than Good?","volume":"14","author":"Tomson C","year":"2019","unstructured":"Tomson C, Tomlinson LA. Stopping RAS Inhibitors to Minimize AKI: More Harm than Good? Clin J Am Soc Nephrol. 2019;14(4):617\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1464689","DOI":"10.3389\/fphar.2024.1464689","article-title":"Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients","volume":"15","author":"Wawruch M","year":"2024","unstructured":"Wawruch M, Petrova M, Celovska D, Alfian SD, Tesar T, Murin J, Trnka M, Paduch T, Aarnio E. Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients. Front Pharmacol. 2024;15:1464689.","journal-title":"Front Pharmacol"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1053\/j.ajkd.2020.04.014","article-title":"Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis","volume":"77","author":"Troost JP","year":"2021","unstructured":"Troost JP, Trachtman H, Spino C, Kaskel FJ, Friedman A, Moxey-Mims MM, Fine RN, Gassman JJ, Kopp JB, Walsh L, et al. Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis. Am J Kidney Dis. 2021;77(2):216\u201325.","journal-title":"Am J Kidney Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fmed.2018.00098","article-title":"Molecular Mechanisms of Proteinuria in Focal Segmental Glomerulosclerosis","volume":"5","author":"Wen Y","year":"2018","unstructured":"Wen Y, Shah S, Campbell KN. Molecular Mechanisms of Proteinuria in Focal Segmental Glomerulosclerosis. Front Med (Lausanne). 2018;5:98.","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1681\/ASN.2005010055","article-title":"Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene","volume":"16","author":"Wharram BL","year":"2005","unstructured":"Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol. 2005;16(10):2941\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"ref32","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1681\/ASN.2021101396","article-title":"Kidney Biopsy Features Most Predictive of Clinical Outcomes in the Spectrum of Minimal Change Disease and Focal Segmental Glomerulosclerosis","volume":"33","author":"Zee J","year":"2022","unstructured":"Zee J, Liu Q, Smith AR, Hodgin JB, Rosenberg A, Gillespie BW, Holzman LB, Barisoni L, Mariani LH. Kidney Biopsy Features Most Predictive of Clinical Outcomes in the Spectrum of Minimal Change Disease and Focal Segmental Glomerulosclerosis. J Am Soc Nephrol. 2022;33(7):1411\u201326.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2215\/CJN.06100612","article-title":"Association of histologic variants in FSGS clinical trial with presenting features and outcomes","volume":"8","author":"D'Agati VD","year":"2013","unstructured":"D'Agati VD, Alster JM, Jennette JC, Thomas DB, Pullman J, Savino DA, Cohen AH, Gipson DS, Gassman JJ, Radeva MK, et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol. 2013;8(3):399\u2013406.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"ref34","first-page":"362","article-title":"Clinical and morphological predictors of renal outcome in adult patients with focal and segmental glomerulosclerosis (FSGS)","volume":"46","author":"Shiiki H","year":"1996","unstructured":"Shiiki H, Nishino T, Uyama H, Kimura T, Nishimoto K, Iwano M, Kanauchi M, Fujii Y, Dohi K. Clinical and morphological predictors of renal outcome in adult patients with focal and segmental glomerulosclerosis (FSGS). Clin Nephrol. 1996;46(6):362\u20138.","journal-title":"Clin Nephrol"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ckj\/sfu100","article-title":"Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations","volume":"7","author":"Sethi S","year":"2014","unstructured":"Sethi S, Zand L, Nasr SH, Glassock RJ, Fervenza FC. Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations. Clin Kidney J. 2014;7(6):531\u20137.","journal-title":"Clin Kidney J"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12882-019-1498-4","article-title":"Focal segmental glomerulosclerosis, excluding atypical lesion, is a predictor of renal outcome in patients with membranous nephropathy: a retrospective analysis of 716 cases","volume":"20","author":"He HG","year":"2019","unstructured":"He HG, Wu CQ, Ye K, Zeng C, Huang YY, Luo SW, Yin W, Ye QR, Peng XM. Focal segmental glomerulosclerosis, excluding atypical lesion, is a predictor of renal outcome in patients with membranous nephropathy: a retrospective analysis of 716 cases. BMC Nephrol. 2019;20(1):328.","journal-title":"BMC Nephrol"},{"issue":"Suppl 3","key":"ref37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ndt\/14.suppl_3.68","article-title":"Clinical picture and outcome of primary focal segmental glomerulosclerosis","volume":"14","author":"Korbet SM","year":"1999","unstructured":"Korbet SM. Clinical picture and outcome of primary focal segmental glomerulosclerosis. Nephrol Dial Transpl. 1999;14(Suppl 3):68\u201373.","journal-title":"Nephrol Dial Transpl"},{"issue":"7","key":"ref38","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/nep.12816","article-title":"Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in Far North Queensland Australian adults","volume":"22","author":"Greenwood AM","year":"2017","unstructured":"Greenwood AM, Gunnarsson R, Neuen BL, Oliver K, Green SJ, Baer RA. Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in Far North Queensland Australian adults. Nephrol (Carlton). 2017;22(7):520\u201330.","journal-title":"Nephrol (Carlton)"},{"year":"2021","author":"Flannery AH","key":"ref39","unstructured":"Flannery AH, Bosler K, Ortiz-Soriano VM, Gianella F, Prado V, Lambert J, Toto RD, Moe OW, Neyra JA. Kidney Biomarkers and Major Adverse Kidney Events in Critically Ill Patients. Kidney360 2021, 2(1):26\u201332."},{"issue":"7","key":"ref40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10916-016-0528-z","article-title":"Identification of Major Adverse Kidney Events Within the Electronic Health Record","volume":"40","author":"Semler MW","year":"2016","unstructured":"Semler MW, Rice TW, Shaw AD, Siew ED, Self WH, Kumar AB, Byrne DW, Ehrenfeld JM, Wanderer JP. Identification of Major Adverse Kidney Events Within the Electronic Health Record. J Med Syst. 2016;40(7):167.","journal-title":"J Med Syst"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler DC","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22\u201331.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000529773","article-title":"Develop and Validate a Risk Score in Predicting Renal Failure in Focal Segmental Glomerulosclerosis","volume":"9","author":"Cai Y","year":"2023","unstructured":"Cai Y, Liu Y, Tong J, Jin Y, Liu J, Hao X, Ji Y, Ma J, Pan X, Chen N, et al. Develop and Validate a Risk Score in Predicting Renal Failure in Focal Segmental Glomerulosclerosis. Kidney Dis (Basel). 2023;9(4):285\u201397.","journal-title":"Kidney Dis (Basel)"},{"issue":"6","key":"ref43","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1038\/sj.ki.4491164","article-title":"Predicting renal survival in primary focal glomerulosclerosis from the time of presentation","volume":"56","author":"Chitalia VC","year":"1999","unstructured":"Chitalia VC, Wells JE, Robson RA, Searle M, Lynn KL. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int. 1999;56(6):2236\u201342.","journal-title":"Kidney Int"},{"issue":"6","key":"ref44","first-page":"408","article-title":"Kidney Outcome in Primary Focal Segmental Glomerulosclerosis (FSGS) by Using a Predictive Model","volume":"15","author":"Ossareh S","year":"2021","unstructured":"Ossareh S, Yahyaei M, Asgari M, Bagherzadegan H, Afghahi H. Kidney Outcome in Primary Focal Segmental Glomerulosclerosis (FSGS) by Using a Predictive Model. Iran J Kidney Dis. 2021;15(6):408\u201318.","journal-title":"Iran J Kidney Dis"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12014-020-09282-x","article-title":"New risk score for predicting steroid resistance in patients with focal segmental glomerulosclerosis or minimal change disease","volume":"17","author":"Weng Q","year":"2020","unstructured":"Weng Q, Zhou Q, Tong J, Jin Y, Liu Y, Yu X, Pan X, Ren H, Wang W, Xie J, et al. New risk score for predicting steroid resistance in patients with focal segmental glomerulosclerosis or minimal change disease. Clin Proteom. 2020;17:18.","journal-title":"Clin Proteom"},{"issue":"12","key":"ref46","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1007\/s11255-022-03254-w","article-title":"Prediction model for the risk of ESKD in patients with primary FSGS","volume":"54","author":"Zhu Y","year":"2022","unstructured":"Zhu Y, Xu W, Wan C, Chen Y, Zhang C. Prediction model for the risk of ESKD in patients with primary FSGS. Int Urol Nephrol. 2022;54(12):3211\u20139.","journal-title":"Int Urol Nephrol"},{"issue":"11","key":"ref47","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1681\/ASN.2018010091","article-title":"DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS","volume":"29","author":"Trachtman H","year":"2018","unstructured":"Trachtman H, Nelson P, Adler S, Campbell KN, Chaudhuri A, Derebail VK, Gambaro G, Gesualdo L, Gipson DS, Hogan J, et al. DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. J Am Soc Nephrol. 2018;29(11):2745\u201354.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"ref48","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1097\/TP.0000000000004985","article-title":"Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study","volume":"108","author":"Shoji J","year":"2024","unstructured":"Shoji J, Goggins WC, Wellen JR, Cunningham PN, Johnston O, Chang SS, Solez K, Santos V, Larson TJ, Takeuchi M, et al. Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study. Transplantation. 2024;108(8):1782\u201392.","journal-title":"Transplantation"},{"issue":"9","key":"ref49","doi-asserted-by":"crossref","first-page":"e0136558","DOI":"10.1371\/journal.pone.0136558","article-title":"Complement Activation in Patients with Focal Segmental Glomerulosclerosis","volume":"10","author":"Thurman JM","year":"2015","unstructured":"Thurman JM, Wong M, Renner B, Frazer-Abel A, Giclas PC, Joy MS, Jalal D, Radeva MK, Gassman J, Gipson DS, et al. Complement Activation in Patients with Focal Segmental Glomerulosclerosis. PLoS ONE. 2015;10(9):e0136558.","journal-title":"PLoS ONE"},{"issue":"12","key":"ref50","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1681\/ASN.2012030302","article-title":"Circulating suPAR in two cohorts of primary FSGS","volume":"23","author":"Wei C","year":"2012","unstructured":"Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, McMahan JL, Radeva M, Heil KM, Trautmann A, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012;23(12):2051\u20139.","journal-title":"J Am Soc Nephrol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-5844460\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-5844460\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T07:30:39Z","timestamp":1754551839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-5844460\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":50,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-5844460\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s12882-025-04334-6","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,5,6]]},"subtype":"preprint"}}